Core Viewpoint - China Biologic Products Holdings (01177.HK) reported a revenue of approximately RMB 31.83 billion for the fiscal year ending December 31, 2025, representing a year-on-year growth of about 10.3% [1] Financial Performance - The sales revenue from innovative products reached approximately RMB 15.22 billion, marking a year-on-year increase of about 26.2%, and accounting for approximately 47.8% of total revenue [1] - The basic profit attributable to equity holders of the parent company was approximately RMB 4.54 billion, reflecting a significant year-on-year growth of 31.4% [1] - Basic earnings per share were reported at 25.22 cents, with the board recommending a final dividend of 5 Hong Kong cents per share [1] Product Approvals - During the reporting period, the company had four innovative products approved by the NMPA, including Setanxin (Kumosili Capsules), Shenghetu® (Zongaitin Tablets), Putanning (Meloxicam Injection® (II)), and Anqixin (Recombinant Human Coagulation Factor VIIa Injection) [1] - Additionally, three Class 1 innovative drugs received NMPA approval for four new indications, including: - Anlotinib combined with Bemarituzumab for first-line treatment of renal cell carcinoma - Anlotinib combined with Paimu Li for first-line treatment of hepatocellular carcinoma - Anlotinib combined with chemotherapy for first-line treatment of soft tissue sarcoma - Paimu Li combined with chemotherapy for first-line treatment of nasopharyngeal carcinoma [1]